Please use this identifier to cite or link to this item:
http://dspace.bits-pilani.ac.in:8080/jspui/handle/123456789/13461Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Gaikwad, Anil Bhanudas | - |
| dc.date.accessioned | 2023-12-20T09:27:39Z | - |
| dc.date.available | 2023-12-20T09:27:39Z | - |
| dc.date.issued | 2019-03 | - |
| dc.identifier.uri | https://www.sciencedirect.com/science/article/abs/pii/S0024320519301171 | - |
| dc.identifier.uri | http://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/13461 | - |
| dc.description.abstract | Renin-angiotensin system (RAS) and natriuretic peptides system (NPS) perturbations govern the development of diabetic nephropathy (DN). Hence, in search of a novel therapy against DN, present study targeted both, NPS and RAS simultaneously using a neprilysin inhibitor (NEPi) in combination with either angiotensin receptor blocker (ARB) or angiotensin-converting enzyme 2 (ACE2) activator. | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Elsevier | en_US |
| dc.subject | Pharmacy | en_US |
| dc.subject | Diabetic nephropathy | en_US |
| dc.subject | Renin-angiotensin system (RAS) | en_US |
| dc.subject | Diabetic nephropathy (DN) | en_US |
| dc.title | Concurrent neprilysin inhibition and renin-angiotensin system modulations prevented diabetic nephropathy | en_US |
| dc.type | Article | en_US |
| Appears in Collections: | Department of Pharmacy | |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.